Medtronic plc (MDT)
Medtronic plc is a global leader in medical technology, specializing in medical devices, therapies, and solutions for various chronic diseases. Founded in 1949 and headquartered in Ireland, the company develops products for areas such as cardiac and vascular care, diabetes management, neurological disorders, and surgical equipment, aiming to improve patient outcomes and healthcare efficiency worldwide.
Dividend History
Investors can expect a dividend payout of $0.71 per share, scheduled to be distributed in 27 days on October 17, 2025
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| October 17, 2025 | $0.71 | 2025-09-26 | 2025-09-26 |
| July 11, 2025 | $0.71 | 2025-06-27 | 2025-06-27 |
| April 11, 2025 | $0.70 | 2025-03-28 | 2025-03-28 |
| January 10, 2025 | $0.70 | 2024-12-27 | 2024-12-27 |
| October 11, 2024 | $0.70 | 2024-09-27 | 2024-09-27 |
Dividends Summary
- Medtronic plc has issued 87 dividend payments over the past 21 years
- The most recent dividend was paid 71 days ago, on July 11, 2025
- The highest dividend payed out to investors during this period was $0.71 per share
- The average dividend paid during this period was $0.37 per share.
Company News
The global bone grafts and substitutes market is projected to grow from USD 3.38 billion in 2025 to USD 5.68 billion by 2034, driven by rising orthopedic disorders, trauma cases, and innovations in biomaterials and 3D printing technologies.
Billionaire Philippe Laffont sold Coatue Management's stake in Super Micro Computer and increased investment in Intuitive Surgical, a surgical robotics pioneer with significant market presence and growth potential in robotic-assisted surgeries.
Medtronic plc has announced a quarterly cash dividend of $0.71 per ordinary share, payable on October 17, 2025, to shareholders of record as of September 26, 2025. This continues the company's 48-year streak of consecutive dividend increases.
Intuitive Surgical, the leading developer of robotic surgical systems, reported strong Q4 2024 results with 18% growth in da Vinci procedure volume. However, the company expects a slowdown in procedure volume growth to 13-16% in 2025.
Medtronic's (MDT) stock suffers as a result of geopolitical complications and supply issues despite an expanding portfolio and strong strategic executions.
